Promising Biotech Stocks Worth Watching – August 17th

Thermo Fisher Scientific, AbbVie, Danaher, Bloom Energy, Vertex Pharmaceuticals, Lumentum, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent shares in companies that use biological research and technology to develop pharmaceuticals, therapies, diagnostics and other life-science innovations. Because these firms often incur high R&D costs and face lengthy regulatory approval processes, their stock prices can be highly volatile but may deliver substantial gains if their clinical trials or products succeed. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

NYSE TMO traded up $4.92 during trading on Friday, reaching $489.96. 2,462,453 shares of the company’s stock were exchanged, compared to its average volume of 3,069,315. The company’s fifty day simple moving average is $434.83 and its 200-day simple moving average is $460.05. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The firm has a market capitalization of $185.01 billion, a PE ratio of 28.34, a P/E/G ratio of 2.61 and a beta of 0.74.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded up $1.97 during trading on Friday, hitting $206.65. 4,430,806 shares of the stock were exchanged, compared to its average volume of 4,938,490. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market capitalization of $365.06 billion, a price-to-earnings ratio of 98.41, a price-to-earnings-growth ratio of 1.33 and a beta of 0.50. The company’s fifty day simple moving average is $191.08 and its 200-day simple moving average is $192.20. AbbVie has a 1-year low of $163.81 and a 1-year high of $218.66.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of DHR stock traded up $0.62 during trading on Friday, reaching $210.84. 3,210,213 shares of the company’s stock were exchanged, compared to its average volume of 4,658,279. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm’s fifty day moving average price is $199.94 and its 200-day moving average price is $199.71. Danaher has a twelve month low of $171.00 and a twelve month high of $279.90. The stock has a market capitalization of $150.97 billion, a PE ratio of 44.86, a PEG ratio of 2.94 and a beta of 0.73.

Bloom Energy (BE)

Bloom Energy Corporation designs, manufactures, sells, and installs solid-oxide fuel cell systems for on-site power generation in the United States and internationally. The company offers Bloom Energy Server, a solid oxide technology that converts fuel, such as natural gas, biogas, hydrogen, or a blend of these fuels into electricity through an electrochemical process without combustion.

NYSE:BE traded up $0.21 during trading hours on Friday, hitting $45.32. The company’s stock had a trading volume of 12,427,549 shares, compared to its average volume of 12,190,416. The company has a market capitalization of $10.60 billion, a P/E ratio of 1,133.28 and a beta of 3.28. Bloom Energy has a twelve month low of $9.02 and a twelve month high of $47.21. The stock has a fifty day simple moving average of $28.57 and a 200-day simple moving average of $23.54. The company has a debt-to-equity ratio of 2.18, a current ratio of 4.99 and a quick ratio of 3.21.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of VRTX stock traded up $2.49 on Friday, hitting $392.79. 1,408,302 shares of the stock were exchanged, compared to its average volume of 2,363,952. The firm’s 50 day moving average is $444.95 and its two-hundred day moving average is $463.94. Vertex Pharmaceuticals has a one year low of $362.50 and a one year high of $519.88. The firm has a market capitalization of $100.71 billion, a PE ratio of 28.08 and a beta of 0.44.

Lumentum (LITE)

Lumentum Holdings Inc. manufactures and sells optical and photonic products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company operates through two segments: Optical Communications (OpComms) and Commercial Lasers (Lasers). The OpComms segment offers components, modules, and subsystems that enable the transmission and transport of video, audio, and data over high-capacity fiber optic cables.

Shares of NASDAQ LITE traded up $1.24 during trading hours on Friday, reaching $115.86. 3,164,639 shares of the stock traded hands, compared to its average volume of 2,892,331. The company’s 50-day simple moving average is $98.59 and its two-hundred day simple moving average is $78.85. The company has a quick ratio of 3.53, a current ratio of 4.37 and a debt-to-equity ratio of 2.26. Lumentum has a 52-week low of $45.65 and a 52-week high of $129.98. The company has a market capitalization of $8.04 billion, a P/E ratio of 503.74 and a beta of 1.33.

Cencora (COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

COR stock traded down $1.59 during midday trading on Friday, hitting $293.28. The stock had a trading volume of 1,109,030 shares, compared to its average volume of 1,230,909. The firm has a market cap of $56.86 billion, a price-to-earnings ratio of 30.17, a price-to-earnings-growth ratio of 1.39 and a beta of 0.58. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora has a 52-week low of $218.65 and a 52-week high of $309.35. The business has a 50-day moving average of $292.70 and a two-hundred day moving average of $279.16.